72 Participants Needed

TEAS for Postoperative Nausea and Vomiting

JF
Alberto A. Uribe Vega - Clinical ...
Overseen ByAlberto Uribe, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The proposed research will utilize electroacupuncture, a type of needleless acupuncture that uses electrostimulation, in a randomized, double blind study, to evaluate the incidence of post-operative nausea and vomiting (PONV) in patients undergoing spinal surgeries with the transcutaneous electrical acupoint stimulation (TEAS) compared to patients without TEAS.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot use anti-nausea or nausea-inducing drugs within 3 days before surgery.

What data supports the effectiveness of the treatment TEAS for postoperative nausea and vomiting?

Research shows that transcutaneous electrical acupoint stimulation (TEAS) is effective in preventing postoperative nausea and vomiting after general anesthesia, according to a meta-analysis of randomized controlled trials.12345

Is transcutaneous electrical acupoint stimulation (TEAS) safe for humans?

The research does not provide specific safety data for TEAS, but it is generally considered a non-invasive and low-risk treatment, similar to acupuncture, which is often used for various conditions.13678

How does the treatment TEAS for postoperative nausea and vomiting differ from other treatments?

TEAS (Transcutaneous Electrical Acupoint Stimulation) is unique because it uses electrical stimulation on specific acupoints on the skin to help manage nausea and vomiting after surgery, unlike traditional medications that are taken orally or intravenously. This method is non-invasive and may offer an alternative for patients who prefer not to use drugs or have difficulty with medication side effects.910111213

Research Team

SB

Sergio Bergese, MD

Principal Investigator

Ohio State University

Eligibility Criteria

This trial is for men and women over 18, with an ASA classification I-III, undergoing elective spinal surgery lasting no more than four hours. Participants must be able to consent. Excluded are those with certain medical conditions like vestibular disease, recent nausea or drug use, poorly controlled diabetes, metal/electrical implants, skin issues at the stimulation site, major psychiatric conditions, recent chemo/radiation therapy or investigational product use.

Inclusion Criteria

My health is good to moderate, with or without severe systemic disease.
I am able and willing to agree to participate.
I am scheduled for a spinal surgery that will last less than 4 hours.
See 1 more

Exclusion Criteria

Documented alcohol or substance abuse within 3 months before the surgery
Any condition, which in the opinion of the investigator would make subject ineligible for participation in the study (history of unstable cardiovascular, pulmonary, renal, hepatic, seizures)
My blood sugar levels are not well-controlled.
See 10 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants undergo spinal surgery with or without TEAS, with monitoring of PONV and opioid consumption

1 day
1 visit (in-person)

Immediate Post-operative Monitoring

Participants are monitored for PONV, opioid consumption, and adverse events for 24 hours post-surgery

24 hours

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 week

Treatment Details

Interventions

  • TEAS
Trial OverviewThe study tests if TEAS (a needleless acupuncture using electrostimulation) can reduce post-operative nausea and vomiting in patients after spinal surgery compared to a group without TEAS. It's a randomized double-blind trial meaning participants are randomly assigned to groups and neither they nor the researchers know who receives which treatment until after the results are collected.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Transcutaneous Electrical Acupoint StimulationExperimental Treatment1 Intervention
Subjects in the "Transcutaneous Electrical Acupoint Stimulation" (TEAS) group will receive 20 minutes of TEAS via ES-130 beginning at the time ondansetron is administered (usually given 30 minutes before the end of surgery), for prevention of PONV.
Group II: No Transcutaneous Electrical Acupoint StimulationPlacebo Group1 Intervention
Subjects in the "No Transcutaneous Electrical Acupoint Stimulation" group will not receive any TEAS, although they will have the acupoints identified and ECG patches placed. The device will not be connected to the electrodes of the ES-130 device at the end of surgery, and no TEAS will be delivered.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Jyoti Pandya

Lead Sponsor

Trials
1
Recruited
70+

Findings from Research

Transcutaneous electrical acupoint stimulation (TEAS) significantly reduces the incidence of postoperative nausea and vomiting (PONV) after general anesthesia, with a relative risk of 0.54 based on a meta-analysis of 14 randomized controlled trials involving 1653 participants.
TEAS not only lowers the need for antiemetic rescue medications but also reduces the incidence of dizziness and pruritus, making it a safe and effective option for managing PONV in postoperative care.
Transcutaneous electrical acupoint stimulation for preventing postoperative nausea and vomiting after general anesthesia: A meta-analysis of randomized controlled trials.Chen, J., Tu, Q., Miao, S., et al.[2022]
Aromatherapy (AT) was found to be 100% effective in managing postdischarge nausea and vomiting (PDNV) in ambulatory surgical patients, compared to 67% effectiveness with standard care (SC).
For postoperative nausea and vomiting (PONV), the AT group had a similar incidence (52%) to the SC group (48%), but overall satisfaction with treatment was high in both groups, indicating that AT is a viable option for managing nausea in surgical patients.
A Comparison of Aromatherapy to Standard Care for Relief of PONV and PDNV in Ambulatory Surgical Patients.Stallings-Welden, LM., Doerner, M., Ketchem, EL., et al.[2019]
Postoperative nausea and vomiting are common and can pose risks for patients after surgery, making effective management important.
Complementary therapies such as acupressure, acupuncture, and aromatherapy may provide relief for patients experiencing these unpleasant symptoms.
Alternative therapy applications for postoperative nausea and vomiting.Chiravalle, P., McCaffrey, R.[2019]

References

Transcutaneous electrical acupoint stimulation for preventing postoperative nausea and vomiting after general anesthesia: A meta-analysis of randomized controlled trials. [2022]
A Comparison of Aromatherapy to Standard Care for Relief of PONV and PDNV in Ambulatory Surgical Patients. [2019]
Alternative therapy applications for postoperative nausea and vomiting. [2019]
An analysis of the management and incidence of postoperative nausea and vomiting. [2022]
Aromatherapy for treatment of postoperative nausea and vomiting. [2021]
Reducing postoperative nausea and vomiting in pediatric patients undergoing anterior cruciate ligament reconstruction: A quality report. [2021]
Consensus guidelines for the management of postoperative nausea and vomiting. [2022]
What do nurses know about postoperative nausea and vomiting? [2009]
Antidiarrhoeal activity of hot water extract of black tea (Camellia sinensis). [2015]
10.United Statespubmed.ncbi.nlm.nih.gov
Perioperative polyphenon E, a green tea extract, does not affect the wound complication rate in mice after sham laparotomy yet has an inhibitory effect on wound healing. [2018]
Perioperative polyphenon E- and siliphos-inhibited colorectal tumor growth and metastases without impairment of gastric or abdominal wound healing in mouse models. [2021]
Prokinetic effect of black tea on gastrointestinal motility. [2019]
The effect of green tea ointment on episiotomy pain and wound healing in primiparous women: A randomized, double-blind, placebo-controlled clinical trial. [2022]